RecruitingEarly Phase 1NCT07290205

Remimazolam NeuroImaging

Neuroimaging of Sedation With Remimazolam


Sponsor

Keith M Vogt

Enrollment

60 participants

Start Date

Mar 27, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task


Eligibility

Min Age: 18 YearsMax Age: 59 Years

Inclusion Criteria1

  • Adults 18-59 years of age, who:

Exclusion Criteria20

  • have a valid email address and valid phone number throughout the study
  • free from any non-MRI compatible implants
  • are pregnant or attempting to conceive
  • body mass index (BMI) \> 35
  • significant memory impairment or hearing loss
  • sleep apnea
  • chronic pain or frequently taking pain medication (including tramadol)
  • chronic medical conditions requiring treatment (hypertension, diabetes, high cholesterol)
  • neurologic disease, including seizures and tremor
  • psychiatric diagnoses, including anxiety, depression, panic, or PTSD
  • a history of any of these medical conditions: abnormal heartbeats (cardiac conduction abnormality or arrhythmia), liver or kidney disease, or significant lung disease
  • severe claustrophobia or MRI intolerance
  • have metal implants or non-removable metal piercings
  • having a history of adverse reaction to midazolam (Versed), lorazepam (Ativan) or another benzodiazepine class medication
  • are allergic to dextran
  • daily alcohol or heavy alcohol use; history of alcohol abuse
  • current daily smoker
  • regular or recent marijuana use (including prescribed/medical marijuana)
  • illicit drug use, i.e., street drugs
  • regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRemimazolam

Subjects in this group will receive an intravenous infusion of this drug, during a portion of the study.

DEVICEPeripheral Nerve Stimulation

Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.


Locations(1)

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07290205


Related Trials